DK3033103T3 - Fremgangsmåde til forbedring af astmasymptomer ved anvendelse af benralizumab - Google Patents

Fremgangsmåde til forbedring af astmasymptomer ved anvendelse af benralizumab Download PDF

Info

Publication number
DK3033103T3
DK3033103T3 DK14836392.2T DK14836392T DK3033103T3 DK 3033103 T3 DK3033103 T3 DK 3033103T3 DK 14836392 T DK14836392 T DK 14836392T DK 3033103 T3 DK3033103 T3 DK 3033103T3
Authority
DK
Denmark
Prior art keywords
benralizumab
astm
symptoms
improving
procedure
Prior art date
Application number
DK14836392.2T
Other languages
English (en)
Inventor
Christine Ward
Lorin Roskos
Bing Wang
Donald Raible
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK3033103T3 publication Critical patent/DK3033103T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK14836392.2T 2013-08-12 2014-08-07 Fremgangsmåde til forbedring af astmasymptomer ved anvendelse af benralizumab DK3033103T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361864950P 2013-08-12 2013-08-12
PCT/US2014/050122 WO2015023508A2 (en) 2013-08-12 2014-08-07 Methods for improving asthma symptoms using benralizumab

Publications (1)

Publication Number Publication Date
DK3033103T3 true DK3033103T3 (da) 2019-08-05

Family

ID=52448839

Family Applications (2)

Application Number Title Priority Date Filing Date
DK14836392.2T DK3033103T3 (da) 2013-08-12 2014-08-07 Fremgangsmåde til forbedring af astmasymptomer ved anvendelse af benralizumab
DK19162585.4T DK3536339T3 (da) 2013-08-12 2014-08-07 Fremgangsmåde til forbedring af astmasymptomer ved anvendelse af benralizumab

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK19162585.4T DK3536339T3 (da) 2013-08-12 2014-08-07 Fremgangsmåde til forbedring af astmasymptomer ved anvendelse af benralizumab

Country Status (18)

Country Link
US (1) US9441047B2 (da)
EP (3) EP3033103B1 (da)
JP (2) JP6803229B2 (da)
KR (1) KR102337601B1 (da)
CN (2) CN111617244A (da)
AU (3) AU2014306960B2 (da)
BR (1) BR112016002462A8 (da)
CA (1) CA2918050C (da)
DK (2) DK3033103T3 (da)
ES (2) ES2740355T3 (da)
HK (2) HK1221647A1 (da)
HU (2) HUE057065T2 (da)
MX (1) MX368474B (da)
PL (2) PL3536339T3 (da)
RU (2) RU2020123894A (da)
SG (1) SG11201600484TA (da)
TR (1) TR201910413T4 (da)
WO (1) WO2015023508A2 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3033104T3 (da) 2013-08-12 2019-06-17 Astrazeneca Ab Fremgangsmåder til forøgelse af forceret eksspiratorisk volumen hos astmatikere ved anvendelse af benralizumab
ES2716906T3 (es) 2013-08-12 2019-06-17 Astrazeneca Ab Métodos para reducir la tasa de exacerbación de asma mediante el uso de benralizumab
KR20160061352A (ko) * 2013-10-15 2016-05-31 메디뮨 엘엘씨 벤랄리주맙을 사용하여 만성 폐쇄성 폐 질환을 치료하는 방법
JP2018538249A (ja) 2015-11-04 2018-12-27 アストラゼネカ アクチボラグ 好酸球性疾患における好酸球標的化治療薬に対する臨床応答の予測変数としてのジペプチジルペプチダーゼ−4およびペリオスチン
US20180056018A1 (en) * 2016-08-31 2018-03-01 Cephalon, Inc. Inhalation Systems, Devices and Methods
TW202214692A (zh) * 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3946256B2 (ja) 1995-09-11 2007-07-18 協和醗酵工業株式会社 ヒトインターロイキン5受容体α鎖に対する抗体
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
EP2270150B2 (en) 1999-04-09 2019-08-07 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
AU2001232304A1 (en) 2000-02-15 2001-08-27 Kyowa Hakko Kogyo Co. Ltd. Eosinophil-specific apoptosis inducer
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
JPWO2005035583A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 Il−5受容体に特異的に結合する抗体組成物
US20060014680A1 (en) 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
EP1931709B1 (en) 2005-10-03 2016-12-07 Xencor, Inc. Fc variants with optimized fc receptor binding properties
PL2068927T3 (pl) * 2007-05-14 2016-06-30 Medimmune Llc Sposoby redukcji poziomów eozynofilii
MX352789B (es) 2010-12-16 2017-12-08 Genentech Inc Anticuerpo anti-il-13 para usarse en tratar un asma o un trastorno respiratorio.
EP2710370A4 (en) * 2011-05-18 2015-01-07 Medimmune Llc METHODS OF DIAGNOSING AND TREATING PULMONARY DISEASES OR DISORDERS
WO2013066780A2 (en) 2011-11-01 2013-05-10 Medimmune, Llc Methods for reducing the frequency and severity of acute exacerbations of asthma
DK3033104T3 (da) 2013-08-12 2019-06-17 Astrazeneca Ab Fremgangsmåder til forøgelse af forceret eksspiratorisk volumen hos astmatikere ved anvendelse af benralizumab
ES2716906T3 (es) 2013-08-12 2019-06-17 Astrazeneca Ab Métodos para reducir la tasa de exacerbación de asma mediante el uso de benralizumab

Also Published As

Publication number Publication date
WO2015023508A2 (en) 2015-02-19
JP6803229B2 (ja) 2020-12-23
MX368474B (es) 2019-10-04
HUE057065T2 (hu) 2022-04-28
AU2014306960B2 (en) 2020-01-16
HK1221647A1 (zh) 2017-06-09
RU2020123894A (ru) 2020-09-18
BR112016002462A8 (pt) 2018-06-12
ES2740355T3 (es) 2020-02-05
AU2014306960A1 (en) 2016-02-04
PL3033103T3 (pl) 2019-10-31
PL3536339T3 (pl) 2022-02-21
EP3033103A2 (en) 2016-06-22
JP2020100653A (ja) 2020-07-02
US9441047B2 (en) 2016-09-13
RU2728578C2 (ru) 2020-07-30
DK3536339T3 (da) 2021-12-20
SG11201600484TA (en) 2016-02-26
AU2020202564A1 (en) 2020-05-07
EP3988114A1 (en) 2022-04-27
EP3033103B1 (en) 2019-06-05
CN111617244A (zh) 2020-09-04
AU2023214323A1 (en) 2023-10-19
CA2918050C (en) 2023-10-03
RU2016108734A (ru) 2017-09-19
EP3536339B1 (en) 2021-10-06
JP2016527326A (ja) 2016-09-08
KR102337601B1 (ko) 2021-12-10
WO2015023508A3 (en) 2015-04-16
CA2918050A1 (en) 2015-02-19
BR112016002462A2 (pt) 2017-09-12
WO2015023508A8 (en) 2015-10-15
ES2901634T3 (es) 2022-03-23
KR20160042123A (ko) 2016-04-18
EP3033103A4 (en) 2017-03-22
HUE045402T2 (hu) 2019-12-30
CN105451761A (zh) 2016-03-30
RU2016108734A3 (da) 2018-06-18
EP3536339A1 (en) 2019-09-11
TR201910413T4 (tr) 2019-08-21
MX2016001195A (es) 2016-07-21
HK1225303A1 (zh) 2017-09-08
US20150044204A1 (en) 2015-02-12

Similar Documents

Publication Publication Date Title
DK3076967T3 (da) Fremgangsmåder til behandling af residuelle symptomer på skizofreni
DK3186376T3 (da) Fremgangsmåder til forbedring af cas9-medieret manipulationseffektivitet
DK3512197T5 (da) Fremgangsmåde til kortlægning af intraprædikationsmodus
DK3225604T3 (da) Fremgangsmåde til fremstilling af flerlagsruder
DK2709613T4 (da) Fremgangsmåder til behandling af hcv
DK2941484T3 (da) Fremgangsmåde til at opnå immunsuppressive dendritriske celler
DK2931188T3 (da) Støtte til forebyggelse af symptomer på femoro acetabulær indeklemning
DK2715352T3 (da) Fremgangsmåde til vurdering af risiko for pml
DK2970379T3 (da) Fremgangsmåder til forhøjelse af proteinrenhed ved anvendelse af protein a-baseret kromatografi
FR2996411B1 (fr) Piege pour frelons
DK3033103T3 (da) Fremgangsmåde til forbedring af astmasymptomer ved anvendelse af benralizumab
DK2836460T3 (da) Fremgangsmåde til fremstilling af graphen
DK2870252T3 (da) Fremgangsmåder ved anvendelse af patatin
DK2849760T3 (da) Fremgangsmåder til oligonukleotid-chelatkompleks
DK2983680T3 (da) Forbedring af organer til transplantation
DK2834229T3 (da) Fremgangsmåde til fremstilling af ccr3-inhibitorer
DK2872536T3 (da) Fremgangsmåde til ekstraktion af biomasse
DK2489276T3 (da) Fremgangsmåde til udvinding af olie
DK3033104T3 (da) Fremgangsmåder til forøgelse af forceret eksspiratorisk volumen hos astmatikere ved anvendelse af benralizumab
DK2701707T3 (da) Fremgangsmåde til behandling af dyskinesi
DK3050961T3 (da) Fremgangsmåde til forbedring af effektiviteten ved inducering af pluripotente stamceller
DK2925854T3 (da) Fremgangsmåde til forbedring af gærstammer
DK2837678T3 (da) Fremgangsmåde til forbedret afsmeltning
DK2809782T3 (da) Forbedret fremgangsmåde til fremstilling af makrokugler
DK3202769T3 (da) Fremgangsmåde til oprensning af phosphaplatinforbindelser